Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30854928 | 1.00 | TLR7 (0.54) | TLR7TLR8 | |
| SCHEMBL5119677 | 0.91 | TLR8 (0.51) | TLR7TLR8 | |
| SCHEMBL1890833 | 0.89 | TLR8 (0.59) | TLR7TLR8 | |
| SCHEMBL31006041 | 0.87 | TLR8 (0.55) | TLR7TLR8 | |
| SCHEMBL5113123 | 0.85 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL6031026 | 0.84 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL1043163 | 0.84 | TLR8 (0.74) | TLR7TLR8 | |
| SCHEMBL5736958 | 0.83 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL4331154 | 0.82 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL4336407 | 0.82 | TLR7 (0.55) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341790-B1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2007-02-14 | — | — | EP | claimed |
| US-7132429-B2 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-11-07 | — | — | US | claimed |
| US-20050148619-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-07-07 | — | — | US | claimed |
| US-20040097542-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | claimed |
| US-20040092545-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-13 | — | — | US | claimed |
| US-6683088-B2 | CAN INDUCE THE BIOSYNTHESIS OF VARIOUS CYTOKINES AND ARE USEFUL IN THERAPY OF VIRAL DISEASES AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-27 | — | — | US | claimed |
| EP-1341790-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | claimed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | claimed |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-12-19 | — | — | US | claimed |
| WO-2002046190-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | claimed |
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200345842-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-05 | — | — | US | disclosed |
| US-10722573-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-07-28 | — | — | US | disclosed |
| US-6677347-B2 | ANTICARCINOGENIC AND ANTITUMOR AGENTS; VIRICIDED, IMMUNOMODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| EP-1341790-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | disclosed |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-12-19 | — | — | US | disclosed |
| WO-2002046190-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092545-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885 |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885 |
| US-20050148619-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885 |
| US-20040097542-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885 |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.